Access all our platforms from a single account.
Countdown to Mar-a-Lago Accord just begun?
Summary: Today we cover the chaos in the gold market on the US moving to tariff certain classes of bullion, Trump's executive order to allow bitcoin and cryptocurrency holdings in 401k accounts, geopolitics and crude, and most importantly, the possibly massive implications of Trump's nomination of Stephen Miran to occupy the empty seat on the Fed Board. Today's pod features Saxo Head of Commodity Strategy Ole Hansen and Saxo Global Head of Macro Strategy John J. Hardy.
Listen to the full episode now or follow the Saxo Market Call on your favorite podcast app.
Today's slide deck for the podcast.
Today’s links
My FX Update from today, wondering if both CHF and GBP can fall, if for very different reasons - sterling for structural reasons, and the Swiss franc as it is singled out by the Trump administration.
With Trump’s appointment of Stephen Miran to the Fed, time to re-read the original piece he wrote that went viral across hedge funds and among the commentariat: A User’s Guide to Restructuring the Global Trading System, reminding everyone the scale of what could be under way, who knows even something resembling a “Mar a Lago Accord”. Is Miran’s appointment to the Fed a step in the direction of getting the US Treasury and Fed on the same page to mobilize a massive initiative to further upend the global trading system and the US dollar’s place in it, now that the tariffs are largely in place?
A reminder for those who aren’t to follow Michael Every’s daily geopolitical updates on X, like the excellent one from today.
ChatGPT 5.0 is out and this is a major upgrade with considerable new possibilities - the OpenAI team runs you through what you can do with it.
For those wondering whether the US economy risks a recession, worth having a look here and considering that for many Americans, it is already in a depression.
Chart of the Day - Novo Nordisk
A bit of relief for the beleaguered Novo stock yesterday, as Eli Lilly’s announced that its pill-form obesity drug didn’t perform as well as some hoped in trials. The pill-game for obesity treatment seems to be the next one for both companies, and Novo claims that its pill may be the best in class once released next year. Its stock has cratered as the market reassessed its competitiveness in the market for injectable obesity treatments and potential growth path. While the stock is up well over 10% from the lows this week, it is useful to zoom out to a weekly chart and, oh my goodness, there is a lot of damage done from the highs above DKK 1,000 per share. To even get started on any climb back higher, the stock needs to quickly erase that massive sell-off bar last week from 464 to 308. At 325 currently, some very heavy lifting indeed required.
Questions and comments, please!
We invite you to send any questions and comments you might have for the podcast team. Whether feedback on the show's content, questions about specific topics, or requests for more focus on a given market area in an upcoming podcast, please get in touch at marketcall@saxobank.com.This content is marketing material and should not be considered investment advice. Trading financial instruments carries risks and historic performance is not a guarantee for future performance.
The instrument(s) mentioned in this content may be issued by a partner, from which Saxo receives promotion, payment or retrocessions. While Saxo receives compensation from these partnerships, all content is conducted with the intention of providing clients with valuable options and information.